Voriconazole Mechanism of Action
• Voriconazole is an extended spectrum triazole antifungal agent • Mechanism of action:
-Inhibition of 14-α-sterol demethylase, thus impairing the synthesis of ergosterol for the cytoplasmic membrane Our Pilot Study § Patients for whom voriconazole was determined to be a suitable antifungal prophylaxis underwent testing for CYP2C19 genotype § Voriconazole was started at 5 mg/kg/dose q12h § Prior (0.5 to 1 hour) to the 9 th dose a voriconazole serum concentration was drawn § Target trough: 1-5 mg/L § Doses were adjusted per protocol until target range was achieved
Voriconazole Spectrum of Activity

Our Pilot Study
• Adjustments made to achieve target voriconazole levels: Level < 1 mg/L • Increase daily dose by 25% (level to be repeated prior to 9 th new dose) Levels ≥ 1 mg/L and ≤ 5 mg/L • Make no changes to therapy (repeat level every week x 1 month, then every 2 weeks for months 2-3) Levels > 5 mg/L • Two doses held and then restarted at 50% of the previous dose (level to be repeated prior to 9 th new dose)
Our Pilot study results
Results
Number (range or %)
Total number of paIents 25
Median age in years 7 (0.8--23)
CYP2C19 genotyping
Extensive metabolizers 17 (68%)
Intermediate Metabolizers 3 (12%)
Poor metabolizers 2 (8%)
Not tested 3 (12%)
Our Pilot study results
Results
Median (range)
Voriconazole serum concentra,ons 1.1 mg/L (<0.1--6.1) 
Days to therapeu,c level
Methods
Results
Number (range or %)
Total number of paIents 21
Median age in years 10.7 (0.8--26.4)
CYP2C19 genotyping
Extensive metabolizers 
Results
Conclusions
• Our results show that CYP450-2C19 genotype directed initial dosing and subsequent dose adjustments per the algorithm can successfully achieve prophylactic voriconazole target levels in pediatric patients undergoing HSCT • Strongly recommend genotype directed dosing in HSCT and establishment of center-specific protocol
Audience Response Question
RJ is a 5-year-old male being transplanted for hemophagocytic lymphohistiocytosis (HLH Questions?
